AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00370149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic-impregnated Catheters (M/R)
Description: Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
Study NCT00370149 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-impregnated Catheters (C/S)
Description: Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
Study NCT00787332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desirudin or Argatroban®
Description: Desirudin 15mg SC Argatroban® IV dosing per Package Insert
Study NCT02621567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright Light Therapy Lamp
Description: TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
Study NCT02621567 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Modified Dim Lamp
Description: TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
Study NCT02891590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRMWXHS-12
Study NCT03801720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Using ultrasound stimulation to induce micturition.
Study NCT02809027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Study NCT02809027 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study NCT04103047 — intervention group
Intervention type: OTHER
Intervention: SAD
Description: The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
Study NCT04307602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - High Intensity Interval Training (HIIT)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
Study NCT04307602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - High Intensity Interval Training (HIIT)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled children
Study NCT04307602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise - Submaximal Steady State Training (SST)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
Study NCT04307602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise - Submaximal Steady State Training (SST)
Description: Exercise in the walk aid Innowalk for children for children with CP GMFCS IV-V, Exercise on spinning bike for children with CP GMFCS I-II and non-disabled
Study NCT01290016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 servings dairy + exercise
Description: Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
Study NCT01290016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 servings dairy + exercise
Description: Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
Study NCT01290016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
Study NCT04443920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
Study NCT02140476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar vessel sealing and cutting device
Description: This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
Study NCT02140476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing and cutting device
Description: This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
Study NCT02140476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thyroidectomy
Description: Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
Study NCT02140476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional thyroidectomy
Description: Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
Study NCT01277042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (CervarixTM)
Description: 3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
Study NCT01277042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-BTM
Description: 3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
Study NCT04443920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Normal Saline (NS)
Description: Randomly assigned \[1:1 ratio\] using a computer generated table of random numbers to 1 of the 2 intervention groups
Study NCT01617083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Antibiotic used to treat infections
Study NCT01617083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thickening compound with sugar and flavoring
Study NCT03503838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Yoga
Description: 12 weeks of online yoga; 60 min/week
Study NCT03149315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg, PO once daily for 2-7 days
Study NCT03306186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HemoSpec
Description: Blood sampling for analysis
Study NCT02662595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS reminder message
Study NCT02662595 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice call + SMS message
Study NCT00948259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP031112
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Study NCT00948259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
Study NCT00635843 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAVERICK™ Disc
Description: The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
Study NCT00635843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft
Description: The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
Study NCT03479060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wet Cupping
Description: cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
Study NCT00688506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combined sono-electro-magnetic therapy (Sonodyn Medico Star)
Description: twice a day for 10 minutes during 12 weeks
Study NCT00688506 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo therapy (Placebo Sonodyn Medico Star)
Description: twice a day for 10 minutes during 12 weeks
Study NCT03696979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial induction therapy
Description: Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
Study NCT03696979 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic pain education
Description: Therapeutic pain education is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
Study NCT01212263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step-up HP u FSH
Description: HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
Study NCT01212263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphine citrate plus low dose uFSH
Description: Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Study NCT00787332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desirudin or Argatroban®
Description: Desirudin 15mg SC Argatroban® IV dosing per Package Insert
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluoruracil
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Study NCT04788719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait analysis
Study NCT02517047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareTRx
Description: CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
Study NCT04359446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NC ( Non- Compliant) Balloon dilatation
Description: NC Balloon dilatation at pressure > NC-RBP (18-20 atm) with > 1 long inflation (> 20 minutes each)
Study NCT04359446 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser Excimer + NC Balloon
Description: Laser Excimer + NC Balloon dilatation at pressure > NC-RBP (18-20 atm) with > 1 long inflation (> 20 minutes each)
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating growth factor
Description: rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
Study NCT00615602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
Study NCT04974502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: Oral hygiene instructions, scaling and root planning.
Study NCT04117061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
Study NCT03826212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean Germ Extract
Description: Soybean Germ Extract 1,600 mg/day for 12 weeks.
Study NCT00690937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric coated sevelamer
Description: Drug treatment
Study NCT00690937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam Cholestagel
Description: Drug comparator
Study NCT00690937 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02549677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: epirubicin, 90mg per square meter, every 3 weeks, day 1
Study NCT02549677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: docetaxel, 75mg per square meter, every 3 weeks, day 1
Study NCT02549677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
Study NCT02549677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1500 mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg fed GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000mg GSK investigational drug
Study NCT00828867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4000mg GSK investigational drug
Study NCT04174131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane + Lidocaine
Description: Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
Study NCT04174131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane® Lyft
Description: Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
Study NCT04270851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LiMAx test
Description: The LiMAx test is a fully licenced liver function test, testing liver maximum capacity via a breath test.
Study NCT04270851 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HepaT1ca magnetic resonance scan
Description: The HepaT1ca scan is a pre-operative magnetic resonance scan providing a detailed report permitting interactive virtual pre-operative planning prior to liver surgery.
Study NCT01682369 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TIV (Aggripal)
Study NCT03826212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1,600 mg/day for 12 weeks.
Study NCT01682369 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ATIV (Fluad)
Study NCT03351361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab
Description: Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
Study NCT03351361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
Study NCT02696720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT02696720 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT01244763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule
Study NCT00164905 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler ultrasound probe
Description: Applying to ulcer base to assess the blood flow underneath the ulcer
Study NCT00421863 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Catapresan TTS 2
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study NCT00995735 — intervention group
Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
Study NCT00995735 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
Study NCT03871881 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
Study NCT01897415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
Study NCT02426242 — intervention group
Intervention type: OTHER
Intervention: Collection of medical data from ICU patients
Description: A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
Study NCT01782183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal camera by Flir -HM series.
Description: The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle